RLMD

RELMADA THERAPEUTICS, INC.

Nasdaq · Pharmaceutical Preparations · Inc. NV · CIK 0001553643
$6.65 +1.99% $697.5M
8 New Institutional Positions3 Institutional Exits
Vol
Market Cap$697.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders39 funds
Inst. Value$261.1M
Inst. Activity8 buys / 3 sells
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. NV·CIK 0001553643·Prev Close $6.52

Recent Activity

May 13, 2026 SEC
Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, registering an indetermin
S-3ASR — Impact 6/10
May 12, 2026 SEC
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net
8-K — Impact 4/10
Apr 17, 2026 SEC
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key proposals: electing two
DEFA14A — Impact 3/10
Inst.
JANUS HENDERSON GROUP PLC — ADD
11,063,862 shares ($76.9M)
Inst.
MARSHALL WACE, LLP — ADD
4,481,606 shares ($31.2M)
Jun 11, 2026 other
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
<p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a href="https://
Mar 19, 2026 Press
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month
Impact 8/10
Mar 12, 2026 Press
Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 f
Impact 3/10

Price Targets

$12.80 +92.5% upside Strong Buy
Current $6.65 Low $9.00 Median $12.00 High $19.00 5 analysts
$9.00 $19.00

Analyst Ratings

Strong Buy91% buy · 11 analysts
4Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Mar 24, 2026 Piper Sandler INITIATE Overweight
Mar 20, 2026 Mizuho MAINTAIN Outperform → Outperform
Mar 2, 2026 LUCID CAPITAL MARKETS INITIATE Buy
Jan 23, 2026 Leerink Partners UPGRADE Market Perform → Outperform
Dec 22, 2025 Jefferies INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.19 $-0.19 — $-0.19 4
Next Q $-0.20 $-0.21 — $-0.20 32% YoY 4
Current FY $-0.41 ▼ -13.9% $-0.41 — $-0.41 63% YoY 1
Next FY $-0.41 ▲ +10.9% $-0.41 — $-0.41 0% YoY 1

Latest Reports

BEARISH S-3ASR 6/10
Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, registering an indetermin
May 13, 2026
NEUTRAL 8-K 4/10
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net
May 12, 2026
BULLISH Press 8/10
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month
Mar 19, 2026

Top Institutional Holders

FundValueMove
JANUS HENDERSON GROUP PLC$76.9MADD
ADAGE CAPITAL PARTNERS GP,$33.2MNEW
MARSHALL WACE, LLP$31.2MADD
VANGUARD CAPITAL MANAGEMENT LLC$21.4M—
RA CAPITAL MANAGEMENT, L.P.$20.5MNEW
39 institutional holders with $261.1M total value (37,526,482 shares) as of 2026-Q1. Top holders: JANUS, ADAGE, MARSHALL. Net buying activity: 8 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1JANUS HENDERSON GROUP PLC11,063,862$76.9M29.5%ADD +52.2%
2ADAGE CAPITAL PARTNERS GP, L.L.C.4,763,158$33.2M12.7%NEW
3MARSHALL WACE, LLP4,481,606$31.2M11.9%ADD +40.5%
4VANGUARD CAPITAL MANAGEMENT LLC3,076,570$21.4M8.2%—
5RA CAPITAL MANAGEMENT, L.P.2,947,369$20.5M7.9%NEW
6DRIEHAUS CAPITAL MANAGEMENT LLC2,132,053$14.8M5.7%DOUBLED +154.1%
7Polar Capital Holdings Plc1,414,621$9.8M3.8%—
8BlackRock, Inc.1,289,550$9.0M3.4%DOUBLED +149.5%
9SUSQUEHANNA INTERNATIONAL GROUP, LLP1,011,572$7.0M2.7%—
10GOLDMAN SACHS GROUP INC699,039$4.9M1.9%—
11AMERIPRISE FINANCIAL INC533,258$3.7M1.4%TRIM -72.2%
12Point72 Asset Management, L.P.504,820$3.5M1.3%DOUBLED +169.4%
13VANGUARD FIDUCIARY TRUST CO449,811$3.1M1.2%—
14Woodline Partners LP421,052$2.9M1.1%—
15TWO SIGMA INVESTMENTS, LP408,095$2.8M1.1%DOUBLED +229.9%
16STATE STREET CORP357,040$2.5M1.0%DOUBLED +215.1%
17SUSQUEHANNA INTERNATIONAL GROUP, LLP281,800$2.0M0.8%—
18BALYASNY ASSET MANAGEMENT L.P.252,457$1.8M0.7%TRIM -53.9%
19DEUTSCHE BANK AG\224,846$1.6M0.6%—
20MORGAN STANLEY198,463$1.4M0.5%DOUBLED +218.3%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
JANUS HENDERSON GROUP PLCADD7,270,00011,063,862+52.2%$76.9M2026-Q1
MARSHALL WACE, LLPADD3,189,6624,481,606+40.5%$31.2M2026-Q1
RA CAPITAL MANAGEMENT, L.P.NEW—2,947,369—$20.5M2026-Q1
AMERIPRISE FINANCIAL INCTRIM1,920,099533,258-72.2%$3.7M2026-Q1
Point72 Asset Management, L.P.DOUBLED187,377504,820+169.4%$3.5M2026-Q1
BALYASNY ASSET MANAGEMENT L.P.TRIM547,854252,457-53.9%$1.8M2026-Q1
MORGAN STANLEYDOUBLED62,357198,463+218.3%$1.4M2026-Q1
SEI INVESTMENTS COADD98,965166,614+68.4%$1.2M2026-Q1
BANK OF AMERICA CORP /DE/DOUBLED25,340125,941+397.0%$876.5K2026-Q1
Hudson Bay Capital Management LPADD26,24742,141+60.6%$293.3K2026-Q1
OMERS ADMINISTRATION CorpTRIM65,90041,600-36.9%$289.5K2026-Q1
JANUS HENDERSON GROUP PLCNEW—7,270,000—$35.0M2025-Q4
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW—4,270,000—$20.6M2025-Q4
MARSHALL WACE, LLPDOUBLED272,0533,189,662+1072.4%$15.4M2025-Q4
DRIEHAUS CAPITAL MANAGEMENT LLCDOUBLED740,0061,880,006+154.1%$9.1M2025-Q4
BlackRock, Inc.DOUBLED508,0001,267,503+149.5%$6.1M2025-Q4
VANGUARD GROUP INCDOUBLED418,5801,203,307+187.5%$5.8M2025-Q4
Corient Private Wealth LLCDOUBLED206,667719,582+248.2%$3.4M2025-Q4
TWO SIGMA INVESTMENTS, LPDOUBLED173,614572,835+229.9%$2.8M2025-Q4
STATE STREET CORPDOUBLED101,820320,820+215.1%$1.5M2025-Q4
MORGAN STANLEYDOUBLED1,03962,357+5901.6%$301.2K2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED26325,340+9535.0%$122.4K2025-Q4
MARSHALL WACE, LLPADD154,568272,053+76.0%$546.8K2025-Q3
TWO SIGMA INVESTMENTS, LPADD95,417173,614+82.0%$349.0K2025-Q3
UBS Group AGTRIM180,47159,785-66.9%$120.2K2025-Q3
∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
BEARISH S-3ASR 6/10
Relmada Therapeutics filed an automatic shelf registration statement (S-3ASR) on May 13, 2026, regis
May 13, 2026
NEUTRAL 8-K 4/10
Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage
May 12, 2026
NEUTRAL DEFA14A 3/10
Relmada Therapeutics is holding its 2026 annual meeting where shareholders will vote on four key pro
Apr 17, 2026
NEUTRAL S-3 3/10
Relmada Therapeutics filed an S-3 shelf registration to register the resale of 33,685,096 shares of
Apr 3, 2026
BULLISH 8/10
Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlightin
Mar 19, 2026
NEUTRAL 3/10
Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4
Mar 12, 2026
NEUTRAL 6/10
Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pr
Mar 9, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 4 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$12.80 mean target +92.5% upside Strong Buy (3.00)
$9.00 Low $19.00 High
MetricValue
Current Price$6.65
Target Low$9.00
Target Mean$12.80
Target Median$12.00
Target High$19.00
# Analysts5
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.19 $-0.19 $-0.19 — — 1↑ 2↓ $0.0B — 4
Next Q
2026-09-30
 $-0.20 $-0.21 $-0.20 31.7% — 1↑ 2↓ $0.0B — 4
Current FY
2026-12-31
 $-0.41 $-0.41 $-0.41 62.8% -13.9% 0↑ 1↓ $0.0B 0.0% 1
Next FY
2027-12-31
 $-0.41 $-0.41 $-0.41 0.0% +10.9% 0↑ 1↓ $0.0B 0.0% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.190
7d ago$0.000-0.190
30d ago$0.000-0.190
60d ago$-0.145-0.045
90d ago$-0.190
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 3 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Mar 24, 2026 Piper Sandler INITIATE — Overweight
Mar 20, 2026 Mizuho MAINTAIN Outperform Outperform
Mar 2, 2026 LUCID CAPITAL MARKETS INITIATE — Buy
Jan 23, 2026 Leerink Partners UPGRADE Market Perform Outperform
Dec 22, 2025 Jefferies INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264610091%
May 1, 20264610091%
Apr 1, 20264610091%
Mar 1, 20264410089%
Feb 1, 20264410089%
Jan 1, 20263410088%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 11, 2026
other
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
<p align="justify">CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- <strong><a href="https://www.globenewswire.com/Tracker?data=jKfBjZl3FcOTXf4
Jun 9, 2026
short_volume
Short Volume: RLMD — 70.6% short (0.5M / 0.7M)
Short: 503,828 | Exempt: 0 | TRF Vol: 713,840 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: RLMD — 76.5% short (0.7M / 0.9M)
Short: 710,839 | Exempt: 0 | TRF Vol: 929,647 | Short Ratio: 76.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: RLMD — 63.0% short (0.9M / 1.4M)
Short: 851,503 | Exempt: 4,615 | TRF Vol: 1,351,958 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: RLMD — 56.8% short (0.3M / 0.5M)
Short: 285,523 | Exempt: 125 | TRF Vol: 502,695 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
RLMD Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
RLMD Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
RLMD Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
earnings
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
<p align="justify">CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a cli
May 5, 2026
other
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
<p align="justify">CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=c7VPKVDkx5VPb1e5e3nJlPKv
Apr 15, 2026
short_volume
Short Volume: RLMD — 62.1% short (0.3M / 0.5M)
Short: 328,744 | Exempt: 9,062 | TRF Vol: 529,526 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: RLMD — 59.6% short (0.4M / 0.6M)
Short: 386,439 | Exempt: 500 | TRF Vol: 648,559 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: RLMD — 69.3% short (0.6M / 0.8M)
Short: 575,576 | Exempt: 2,249 | TRF Vol: 830,239 | Short Ratio: 69.3% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_volume
Short Volume: RLMD — 75.4% short (0.4M / 0.5M)
Short: 390,476 | Exempt: 0 | TRF Vol: 517,689 | Short Ratio: 75.4% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: RLMD — 59.5% short (0.3M / 0.5M)
Short: 318,335 | Exempt: 0 | TRF Vol: 535,436 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)